Kestra Medical Technologies (NASDAQ:KMTS) Trading Up 7% – Should You Buy?

Shares of Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) shot up 7% during mid-day trading on Tuesday . The company traded as high as $20.45 and last traded at $20.60. 63,639 shares traded hands during trading, a decline of 78% from the average session volume of 287,193 shares. The stock had previously closed at $19.26.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on KMTS shares. The Goldman Sachs Group set a $24.00 price target on shares of Kestra Medical Technologies in a research report on Friday, January 16th. Stifel Nicolaus set a $30.00 price target on shares of Kestra Medical Technologies in a report on Friday, December 12th. BTIG Research started coverage on shares of Kestra Medical Technologies in a research report on Tuesday, November 18th. They issued a “buy” rating and a $32.00 target price on the stock. Piper Sandler increased their target price on shares of Kestra Medical Technologies from $27.00 to $30.00 and gave the stock an “overweight” rating in a report on Friday, December 12th. Finally, Wells Fargo & Company lifted their price objective on Kestra Medical Technologies from $27.00 to $28.00 and gave the company an “overweight” rating in a research report on Friday, December 12th. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $29.00.

Kestra Medical Technologies Stock Performance

The stock has a market cap of $1.21 billion and a price-to-earnings ratio of -6.55. The firm’s 50-day moving average price is $24.42 and its two-hundred day moving average price is $24.53. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.47 and a current ratio of 5.47.

Insider Activity at Kestra Medical Technologies

In other Kestra Medical Technologies news, insider Brian Daniel Webster sold 15,000 shares of the company’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $25.60, for a total value of $384,000.00. Following the sale, the insider owned 379,786 shares of the company’s stock, valued at $9,722,521.60. This represents a 3.80% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Traci S. Umberger sold 10,500 shares of the company’s stock in a transaction that occurred on Monday, December 29th. The shares were sold at an average price of $26.69, for a total transaction of $280,245.00. Following the transaction, the insider directly owned 136,633 shares in the company, valued at $3,646,734.77. The trade was a 7.14% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 55,500 shares of company stock valued at $1,405,095. 3.60% of the stock is owned by company insiders.

Institutional Investors Weigh In On Kestra Medical Technologies

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD raised its holdings in shares of Kestra Medical Technologies by 137.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,369,429 shares of the company’s stock worth $115,878,000 after purchasing an additional 2,529,851 shares during the period. Brown Advisory Inc. lifted its position in shares of Kestra Medical Technologies by 34.1% in the 4th quarter. Brown Advisory Inc. now owns 1,688,356 shares of the company’s stock valued at $44,775,000 after acquiring an additional 428,996 shares in the last quarter. Alliancebernstein L.P. grew its position in Kestra Medical Technologies by 13.7% during the third quarter. Alliancebernstein L.P. now owns 1,491,970 shares of the company’s stock valued at $35,449,000 after purchasing an additional 179,885 shares in the last quarter. Eventide Asset Management LLC increased its holdings in Kestra Medical Technologies by 5.4% in the fourth quarter. Eventide Asset Management LLC now owns 1,269,651 shares of the company’s stock worth $33,671,000 after buying an additional 65,288 shares during the last quarter. Finally, Franklin Resources Inc. increased its holdings in shares of Kestra Medical Technologies by 180.8% during the 4th quarter. Franklin Resources Inc. now owns 951,008 shares of the company’s stock valued at $25,221,000 after acquiring an additional 612,343 shares during the last quarter.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.